> ## Content Index > Fetch the complete content index at: https://med-techinsights.com/llms.txt > Use this file to discover other available public pages before exploring further. # Femtech and R&D Tax Relief: A Growing Opportunity for Innovation - URL: https://med-techinsights.com/femtech-and-rd-tax-relief-a-growing-opportunity-for-innovation/ - Published: 2025-02-26T16:09:20.000Z - Updated: 2026-10-22T08:03:41.000Z - Description: FemTech, the sector focused on technology-driven women’s health solutions, is experiencing rapid growth. However, unique challenges exist in research, development, and innovation within this space. Sarah Bandy, assistant research and development manager and Kanika Mishra-Pathak, tax director at MHA - Author: Olivia Friett - Tags: Insights, Femtech, Research & Development *FemTech, the sector focused on technology-driven women’s health solutions, is experiencing rapid growth. However, unique challenges exist in research, development, and innovation within this space. Sarah Bandy, assistant research and development manager and Kanika Mishra-Pathak, tax director at* [*MHA Accountants and Advisors*](https://www.mha.co.uk/?ref=med-techinsights.com) *explore these challenges, and examine strategies for successful FemTech development.* [FemTech](https://www.med-technews.com/femtech?ref=med-techinsights.com) encompasses a broad range of digital health solutions addressing women’s specific health needs, from menstrual tracking and fertility assistance to menopause management and chronic disease support. While the sector holds immense promise, FemTech companies face distinct challenges in bringing their innovations to market and achieving sustainable growth. **Challenges in FemTech R&D** Compared to other health tech sectors, FemTech R&D is often hindered by: **Data privacy and security:** FemTech solutions collect highly sensitive personal data, raising concerns about privacy and security. Regulatory frameworks, like GDPR in Europe and HIPAA in the U.S., are evolving, but ambiguities remain, particularly regarding fertility data. Building and maintaining user trust is paramount, especially as access to reproductive healthcare faces increasing restrictions globally. **Data availability:** Historical underrepresentation of women in clinical trials has created a significant data gap in understanding female physiology. This lack of comprehensive data can hamper the development and validation of effective FemTech solutions. **Funding limitations:** FemTech startups often struggle to secure funding compared to companies addressing broader health issues. This disparity can be attributed to a combination of factors, including gender bias in investment, the perceived niche market of women’s health, and the higher costs associated with research and trials for female-specific conditions. **Regulatory ambiguity:** Regulatory pathways for female-specific health products are often unclear or underdeveloped. This ambiguity can lead to delays in product approvals and increase the complexity of navigating different markets. FemTech has the potential to revolutionise women’s healthcare, but success requires navigating unique challenges and embracing opportunities for innovation. By prioritising inclusivity, rigorous research, and responsible data practices, FemTech companies can create impactful solutions that improve the lives of women globally. **Leveraging R&D Tax Credits** Given the significant investment required for research and development in FemTech, companies should explore available resources to support their efforts. R&D tax credits, such as those offered in the UK, can provide valuable financial relief for eligible companies and aid with scaling operations up. These incentives can help offset the costs of staff, subcontractors, consumables, and software directly used in R&D activities. To maximise the benefits of R&D tax credits, FemTech companies should: - Carefully document all qualifying R&D activities and expenditures. - Prepare a comprehensive technical report clearly outlining the scientific or technological uncertainties addressed in their projects. - Seek expert advice from R&D tax specialists to navigate the complexities of the claim process. By strategically leveraging R&D tax credits, FemTech companies can reinvest those savings into further innovation, accelerating the development of impactful solutions and driving the growth of this vital sector. **R&D Tax Credit claims checklist** Claiming an R&D tax credit from HMRC is a complex process, but the potential rewards make it worthwhile for eligible companies. Here’s a breakdown of the stages involved: **1\. Project assessment & eligibility:** - **Identify qualifying projects:** Begin by carefully reviewing your activities to pinpoint projects that qualify for R&D tax relief. A qualifying project must seek to advance overall knowledge or capability in a field of science or technology through the resolution of scientific uncertainty. It’s worth noting that software development, manufacturing processes, engineering, scientific research, and even some design work can qualify. **2\. Expenditure identification & calculation:** - **Direct staff costs:** Salaries, wages, National Insurance contributions, and pension contributions for employees directly engaged in R&D activities. - **EPWs (Externally Provided Workers):** This covers temporary staff provided by an agency, but there are restrictions on the expenditure that can be included here. - **Subcontracted R&D:** For work outsourced to another company, you can claim 65% of the costs. HMRC scrutinises subcontracting closely, especially if it involves connected parties or offshoring. - **Consumables:** Materials and resources used directly in the R&D process (e.g., chemicals, prototypes, software licenses). - **Software:** Costs for software directly used in R&D (but not general office software). - **Clinical trial volunteers:** Payments to volunteers in clinical trials. - **Prototype development:** Costs associated with designing and building prototypes for testing and development. - **Cloud computing costs:** Expenses related to cloud services used for R&D. - **Data licenses:** Costs for accessing and using specific datasets for R&D purposes. **3\. Documentation & reporting:** - **Technical report:** A comprehensive report is crucial, explaining the R&D projects, the technological challenges, how you approached them, and the outcomes. This report should be clear, concise, and persuasive to an HMRC inspector. - **Financial records:** Detailed records of all qualifying R&D expenditure are essential. This includes timesheets, invoices, and receipts to support your claim. - **Additional information form (AIF):** This form accompanies your Company Tax Return and provides specific information about your R&D projects and costs, drawing from your technical report and financial records. **4\. Submission and review:** - **Company Tax Return (CT600):** The R&D claim is made through your company’s tax return. - **HMRC Enquiry:** It is possible that HMRC will enquire into your claim, requesting further information or clarification. A well-prepared claim with strong supporting documentation will make this significantly less likely to occur. **Key tips for a successful claim:** **Start early:** Gathering information and preparing the necessary documentation takes time. **Seek expert advice:** For large or complex claims, consider engaging specialist R&D tax advisors. They can help you navigate the process, maximise your claim, and present a robust case to HMRC. **Keep it clear:** Ensure your technical report and supporting documentation are easily understandable and free of jargon. HMRC inspectors need to grasp the essence of your R&D activities. **Be honest and accurate:** Only claim for eligible expenditure and provide accurate information. Any attempt to mislead HMRC could have serious consequences. The Femtech industry is at the forefront of technological innovation in women’s health, addressing long-standing medical challenges with advanced digital health, AI, and biomedical engineering solutions. Given the significant R&D efforts required to develop novel Femtech products, companies operating in this space should assess their eligibility for R&D tax relief, a valuable financial incentive that can accelerate growth and innovation. By strategically leveraging R&D tax credits, Femtech businesses can secure funding, reduce development costs, and bring groundbreaking solutions to market faster. As the sector continues to expand, ensuring alignment with the DSIT Guidelines will be critical for companies looking to maximise their R&D tax claims while driving impactful advancements in female healthcare.